home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »

news

Oct19CRG Enhances Healthcare Financing Investment Team with the Hiring of Scott Li


HOUSTON, TX, October 19, 2015 – CRG, a healthcare-focused investment firm delivering pioneering growth capital solutions to the global healthcare market, announced today that Scott Li has joined the firm as a Principal in CRG’s New York office. 

 

Mr. Li brings over a decade of healthcare industry financing experience, having served as an advisor, investor and executive to a range of healthcare products, technology and services businesses.  Most recently, Mr. Li was a Vice President with Hammond Hanlon Camp LLC (“H2C”), where he advised on M&A engagements for healthcare services clients.

 

Prior to joining H2C, Mr. Li was the Chief Financial Officer of pingmd, an innovative, venture-backed online communication platform for primary care physicians. In that role, he managed the company's financial functions, business development activities and interaction with investors. Over his career, Mr. Li provided financial advice to companies in healthcare and other industries while serving as an Associate in Lazard’s Life Sciences Investment Banking Group, an Analyst in JP Morgan’s North American M&A Group, and an Associate with ABS Ventures, the venture capital arm of DB Capital Partners.

 

“Scott’s substantial healthcare and financial services experience and broad industry relationships will contribute significantly to CRG team strengths in sourcing, structuring and executing flexible growth capital financing solutions to our healthcare business partners,” said Nate Hukill, CRG’s President.

 

With approximately $2.0 billion of assets under management invested across 40 global healthcare investments, CRG currently is investing out of its third fund, CRG Partners III LP (“CRG III” or the “Fund”).  In the six months since the Fund’s inception, CRG III has completed three healthcare financings in Outset Medical, Inc., Avinger, Inc., and GenomeDx Biosciences, a diverse group of public and private commercial-stage healthcare companies which are backed by leading healthcare equity investors.  

 

“We continue to build one of the finest healthcare investment teams in our industry. Our team consists of seasoned healthcare financing industry specialists who offer an array of customized debt and equity investment solutions to support the innovation and growth needs of our portfolio partners.  The CRG team works hand-in-hand with an unparalleled network of global healthcare industry experts, providing a winning combination that supports fund sourcing, diligence and post-investment value strategies on behalf of our business and investing partners,” Mr. Hukill concluded.

 

About CRG

 

Founded in 2003, CRG (previously known as Capital Royalty L.P.) is a healthcare-focused investment firm that delivers pioneering growth capital financing solutions to the global healthcare industry. With approximately $2 billion of assets under management across 40 healthcare investments, CRG provides growth capital to healthcare companies primarily through structured debt and senior secured loans. CRG works across the spectrum of life science products, technologies and services and targets investment sizes ranging between $20 million and $200 million. The firm partners with innovative, commercial-stage healthcare companies that address large, unmet medical needs and are seeking flexible financing solutions with a committed, value-add partner to achieve their growth objectives. CRG is headquartered in Houston, Texas with offices in Boulder, Colorado and New York, New York.

 

For additional information, please visit www.crglp.com.